Castleman disease

Korean Journal of Hematology

Volumn 47, Issue 3, 2012, Pages 163-177

  Saeed Abdul Rahman, Ibrahiem ^a   Al Amri, Ali M ^a  

^a IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

Castleman disease; Human immunodeficiency virus; Hyaline vascular variant; Multicentric castleman disease; Plasma cell variant; Unicentric

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CIDOFOVIR; CYCLOPHOSPHAMIDE; DOXORUBICIN; FOSCARNET; GANCICLOVIR; GLUCOCORTICOID; INTERLEUKIN 6; MONOCLONAL ANTIBODY; PREDNISONE; RECOMBINANT ALPHA INTERFERON; RETINOIC ACID; RITUXIMAB; THALIDOMIDE; VASCULOTROPIN; VINCRISTINE;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANGIOGENESIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; EXCISION; HERPES VIRUS INFECTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPES VIRUS 8 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOBLAST; KAPOSI SARCOMA; LYMPH NODE HYPERPLASIA; LYMPHOCYTE PROLIFERATION; NONHODGKIN LYMPHOMA; PATHOGENESIS; PLASMA CELL; POEMS SYNDROME; RADIOGRAPHY; REVIEW; SPLENOMEGALY;

EID: 84874062502     PISSN: 17387949     EISSN: 20929129     Source Type: Journal    
DOI: 10.5045/kjh.2012.47.3.163     Document Type: Review

References (124)

1. Castleman B, Towne VW. Case records of the Massachusetts General Hospital: Case No. 40231. N Engl J Med 1954;250:1001-5.
2. Moore DF, Preti A, Tran SM. Prognostic implications following an indeterminate diagnostic work-up of lymphoma. Blood 1996;88(Suppl 1):abst 229.
3. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 1956;9: 822-30.
4. Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 1972;29:670-83.
5. Gaba AR, Stein RS, Sweet DL, Variakojis D. Multicentric giant lymph node hyperplasia. Am J Clin Pathol 1978;69:86-90.
6. Martin JM, Bell B, Ruether BA. Giant lymph node hyperplasia (Castleman's disease) of hyaline vascular type. Clinical heterogeneity with immunohistologic uniformity. Am J Clin Pathol 1985;84:439-46.
7. Menke DM, Tiemann M, Camoriano JK, et al. Diagnosis of Castleman's disease by identification of an immunophenotypically aberrant population of mantle zone B lymphocytes in paraffin-embedded lymph node biopsies. Am J Clin Pathol 1996;105:268-76.
8. Menke DM. Ly-1b cells and Castleman disease. Blood 2000;96: 1614-6.
9. Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 2000;95:1406-12.
10. Lachant NA, Sun NC, Leong LA, Oseas RS, Prince HE. Multicentric angiofollicular lymph node hyperplasia (Castleman's disease) followed by Kaposi's sarcoma in two homosexual males with the acquired immunodeficiency syndrome (AIDS). Am J Clin Pathol 1985;83:27-33.
11. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994;266:1865-9.
12. Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N Engl J Med 1995;332:1181-5.
13. Buonaguro FM, Tornesello ML, Beth-Giraldo E, et al. Herpesvirus-like DNA sequences detected in endemic, classic, iatrogenic and epidemic Kaposi's sarcoma (KS) biopsies. Int J Cancer 1996;65:25-8.
14. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDSrelated body-cavity-based lymphomas. N Engl J Med 1995; 332:1186-91.
15. Luppi M, Barozzi P, Schulz TF, et al. Bone marrow failure associated with human herpesvirus 8 infection after transplantation. N Engl J Med 2000;343:1378-85.
16. Kapelushnik J, Ariad S, Benharroch D, et al. Post renal transplantation human herpesvirus 8-associated lymphoproliferative disorder and Kaposi's sarcoma. Br J Haematol 2001;113:425-8.
17. Matsushima AY, Strauchen JA, Lee G, et al. Posttransplantation plasmacytic proliferations related to Kaposi's sarcoma-associated herpesvirus. Am J Surg Pathol 1999;23:1393-400.
18. Rywlin AM, Rosen L, Cabello B. Coexistence of Castleman's disease and Kaposi's sarcoma. Report of a case and a speculation. Am J Dermatopathol 1983;5:277-81.
19. Chen KT. Multicentric Castleman's disease and Kaposi's sarcoma. Am J Surg Pathol 1984;8:287-93.
20. Oksenhendler E, Duarte M, Soulier J, et al. Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS 1996;10:61-7.
21. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcomaassociated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995;86:1276-80.
22. Dupin N, Fisher C, Kellam P, et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A 1999;96:4546-51.
23. Parravicini C, Corbellino M, Paulli M, et al. Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman's disease. Am J Pathol 1997;151:1517-22.
24. Seliem RM, Griffith RC, Harris NL, et al. HHV-8+, EBV+ multicentric plasmablastic microlymphoma in an HIV+ Man: the spectrum of HHV-8+ lymphoproliferative disorders expands. Am J Surg Pathol 2007;31:1439-45.
25. Du MQ, Liu H, Diss TC, et al. Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood 2001;97:2130-6.
26. Oksenhendler E, Boulanger E, Galicier L, et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 2002;99:2331-6.
27. Du MQ, Bacon CM, Isaacson PG. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders. J Clin Pathol 2007;60:1350-7.
28. Dupin N, Gorin I, Deleuze J, Agut H, Huraux JM, Escande JP. Herpes-like DNA sequences, AIDS-related tumors, and Castleman's disease. N Engl J Med 1995;333:798-9.
29. Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. Blood 2000; 96:2069-73.
30. Bower M, Newsom-Davis T, Naresh K, et al. Clinical features and outcome in HIV-associated multicentric Castleman's disease. J Clin Oncol 2011;29:2481-6.
31. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006;2:619-26.
32. Vinzio S, Ciarloni L, Schlienger JL, Rohr S, Méchine A, Goichot B. Isolated microcytic anemia disclosing a unicentric Castleman disease: The interleukin-6/hepcidin pathway? Eur J Intern Med 2008;19:367-9.
33. Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 2007;110:1911-28.
34. Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest 1990;86:592-9.
35. Katsume A, Saito H, Yamada Y, et al. Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice. Cytokine 2002;20:304-11.
36. Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989;74:1360-7.
37. Nishi J, Arimura K, Utsunomiya A, et al. Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman's disease. Br J Haematol 1999;104:482-5.
38. Foss HD, Araujo I, Demel G, Klotzbach H, Hummel M, Stein H. Expression of vascular endothelial growth factor in lymphomas and Castleman's disease. J Pathol 1997;183:44-50.
39. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996;271:736-41.
40. Nguyen DT, Diamond LW, Hansmann ML, et al. Castleman's disease. Differences in follicular dendritic network in the hyaline vascular and plasma cell variants. Histopathology 1994;24:437-43.
41. Sun X, Chang KC, Abruzzo LV, Lai R, Younes A, Jones D. Epidermal growth factor receptor expression in follicular dendritic cells: a shared feature of follicular dendritic cell sarcoma and Castleman's disease. Hum Pathol 2003;34:835-40.
42. Cella M, Jarrossay D, Facchetti F, et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 1999;5:919-23.
43. Kojima M, Motoori T, Nakamura S. Benign atypical and malignant lymphoproliferative disorders in rheumatoid arthritis patients. Biomed Pharmacother 2006;60:663-72.
44. Weisenburger DD, Nathwani BN, Winberg CD, Rappaport H. Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases. Hum Pathol 1985;16:162-72.
45. Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol 2005;129:3-17.
46. Peterson BA, Frizzera G. Multicentric Castleman's disease. Semin Oncol 1993;20:636-47.
47. Frizzera G, Peterson BA, Bayrd ED, Goldman A. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 1985;3:1202-16.
48. Burger R, Neipel F, Fleckenstein B, et al. Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells. Blood 1998;91:1858-63.
49. Aaron L, Lidove O, Yousry C, Roudiere L, Dupont B, Viard JP. Human herpesvirus 8-positive Castleman disease in human immunodeficiency virus-infected patients: the impact of highly active antiretroviral therapy. Clin Infect Dis 2002;35:880-2.
50. Zietz C, Bogner JR, Goebel FD, Löhrs U. An unusual cluster of cases of Castleman's disease during highly active antiretroviral therapy for AIDS. N Engl J Med 1999;340:1923-4.
51. Kessler E, Beer R. Multicentric giant lymph node hyperplasia clinically simulating angioimmunoblastic lymphadenopathy. Associated Kaposi's sarcoma in two of three cases. Isr J Med Sci 1983;19:230-4.
52. Kessler E. Multicentric giant lymph node hyperplasia. A report of seven cases. Cancer 1985;56:2446-51.
53. Dickson D, Ben-Ezra JM, Reed J, Flax H, Janis R. Multicentric giant lymph node hyperplasia, Kaposi's sarcoma, and lymphoma. Arch Pathol Lab Med 1985;109:1013-8.
54. De Rosa G, Barra E, Guarino M, Gentile R. Multicentric Castleman's disease in association with Kaposi's sarcoma. Appl Pathol 1989;7:105-10.
55. Harris NL. Hypervascular follicular hyperplasia and Kaposi's sarcoma in patients at risk for AIDS. N Engl J Med 1984; 310:462-3.
56. Lowenthal DA, Filippa DA, Richardson ME, Bertoni M, Straus DJ. Generalized lymphadenopathy with morphologic features of Castleman's disease in an HIV-positive man. Cancer 1987;60: 2454-8.
57. Su IJ, Hsu YS, Chang YC, Wang IW. Herpesvirus-like DNA sequence in Kaposi's sarcoma from AIDS and non-AIDS patients in Taiwan. Lancet 1995;345:722-3.
58. Huang YQ, Li JJ, Kaplan MH, et al. Human herpesvirus-like nucleic acid in various forms of Kaposi's sarcoma. Lancet 1995;345:759-61.
59. Dupin N, Grandadam M, Calvez V, et al. Herpesvirus-like DNA sequences in patients with Mediterranean Kaposi's sarcoma. Lancet 1995;345:761-2.
60. Ambroziak JA, Blackbourn DJ, Herndier BG, et al. Herpes-like sequences in HIV-infected and uninfected Kaposi's sarcoma patients. Science 1995;268:582-3.
61. Boshoff C, Whitby D, Hatziioannou T, et al. Kaposi's-sarcomaassociated herpesvirus in HIV-negative Kaposi's sarcoma. Lancet 1995;345:1043-4.
62. Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: definitions and long-term outcome. Blood 2003;101:2496-506.
63. Belec L, Mohamed AS, Authier FJ, et al. Human herpesvirus 8 infection in patients with POEMS syndrome-associated multicentric Castleman's disease. Blood 1999;93:3643-53.
64. Gherardi RK, Bélec L, Fromont G, et al. Elevated levels of interleukin-1 beta (IL-1 beta) and IL-6 in serum and increased production of IL-1 beta mRNA in lymph nodes of patients with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome. Blood 1994;83:2587-93.
65. McAdams HP, Rosado-de-Christenson M, Fishback NF, Templeton PA. Castleman disease of the thorax: radiologic features with clinical and histopathologic correlation. Radiology 1998; 209:221-8.
66. Johkoh T, Müller NL, Ichikado K, et al. Intrathoracic multicentric Castleman disease: CT findings in 12 patients. Radiology 1998;209:477-81.
67. Reynolds SP, Gibbs AR, Weeks R, Adams H, Davies BH. Massive pleural effusion: an unusual presentation of Castleman's disease. Eur Respir J 1992;5:1150-3.
68. Gibbons JA, Rosencrantz H, Posey DJ, Watts M. Angiofollicular lymphoid hyperplasis (Castleman's tumor) resembling a pericardial cyst: differentiation by computerized tomography. Ann Thorac Surg 1981;32:193-6.
69. Stavridis GT, Lau OJ. Castleman's disease arising from the intercostal space. Eur J Cardiothorac Surg 1993;7:218-9.
70. Meador TL, McLarney JK. CT features of Castleman disease of the abdomen and pelvis. AJR Am J Roentgenol 2000;175:115-8.
71. Kim TJ, Han JK, Kim YH, Kim TK, Choi BI. Castleman disease of the abdomen: imaging spectrum and clinicopathologic correlations. J Comput Assist Tomogr 2001;25:207-14.
72. Herrada J, Cabanillas F, Rice L, Manning J, Pugh W. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 1998;128:657-62.
73. Bowne WB, Lewis JJ, Filippa DA, et al. The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. Cancer 1999;85:706-17.
74. Bucher P, Chassot G, Zufferey G, Ris F, Huber O, Morel P. Surgical management of abdominal and retroperitoneal Castleman's disease. World J Surg Oncol 2005;3:33.
75. Chronowski GM, Ha CS, Wilder RB, Cabanillas F, Manning J, Cox JD. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer 2001;92:670-6.
76. Dispenzieri A, Gertz MA. Treatment of Castleman's disease. Curr Treat Options Oncol 2005;6:255-66.
77. Scott D, Cabral L, Harrington WJ Jr. Treatment of HIV-associated multicentric Castleman's disease with oral etoposide. Am J Hematol 2001;66:148-50.
78. Kumari P, Schechter GP, Saini N, Benator DA. Successful treatment of human immunodeficiency virus-related Castleman's disease with interferon-alpha. Clin Infect Dis 2000; 31:602-4.
79. Kotb R, Vincent I, Dulioust A, et al. Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease. Eur J Haematol 2006;76: 269-71.
80. Emson HE. Extrathoracic angiofollicular lymphoid hyperplasia with coincidental myasthenia gravis. Cancer 1973;31:241-5.
81. Weisenburger DD, DeGowin RL, Gibson P, Armitage JO. Remission of giant lymph node hyperplasia with anemia after radiotherapy. Cancer 1979;44:457-62.
82. Nordstrom DG, Tewfik HH, Latourette HB. Giant lymph node hyperplasia: a review of literature and report of two cases of plasma cell variant responding to radiation therapy. Int J Radiat Oncol Biol Phys 1978;4:1045-8.
83. Fitzpatrick PJ, Brown TC. Angiofollicular lymph node hyperplasia. Can Med Assoc J 1968;99:1259-62.
84. Stokes SH, Griffith RC, Thomas PR. Angiofollicular lymph node hyperplasia (Castleman's disease) associated with vertebral destruction. Cancer 1985;56:876-9.
85. Sethi T, Joshi K, Sharma SC, Gupta BD. Radiation therapy in the management of giant lymph node hyperplasia. Br J Radiol 1990;63:648-50.
86. Massey GV, Kornstein MJ, Wahl D, Huang XL, McCrady CW, Carchman RA. Angiofollicular lymph node hyperplasia (Castleman's disease) in an adolescent female. Clinical and immunologic findings. Cancer 1991;68:1365-72.
87. Veldhuis GJ, van der Leest AH, de Wolf JT, de Vries EG, Vellenga E. A case of localized Castleman's disease with systemic involvement: treatment and pathogenetic aspects. Ann Hematol 1996;73:47-50.
88. Neuhof D, Debus J. Outcome and late complications of radiotherapy in patients with unicentric Castleman disease. Acta Oncol 2006;45:1126-31.
89. Nikolskaia OV, Nousari CH, Anhalt GJ. Paraneoplastic pemphigus in association with Castleman's disease. Br J Dermatol 2003;149:1143-51.
90. Feremans WW, Khodadadi E. Alpha-interferon therapy in refractory angioimmunoblastic lymphadenopathy. Eur J Haematol 1987;39:91.
91. Tamayo M, Gonzalez C, Majado MJ, Candel R, Ramos J. Long-term complete remission after interferon treatment in a case of multicentric Castelman's disease. Am J Hematol 1995; 49:359-60.
92. Andres E, Maloisel F. Interferon-alpha as first-line therapy for treatment of multicentric Castleman's disease. Ann Oncol 2000;11:1613-4.
93. Kane KF, Langman MJ, Williams GR. Antiproliferative responses to two human colon cancer cell lines to vitamin D3 are differently modified by 9-cis-retinoic acid. Cancer Res 1996; 56:623-32.
94. Zancai P, Cariati R, Quaia M, et al. Retinoic acid inhibits IL-6-dependent but not constitutive STAT3 activation in Epstein-Barr virus-immortalized B lymphocytes. Int J Oncol 2004;25:345-55.
95. Rieu P, Droz D, Gessain A, Grünfeld JP, Hermine O. Retinoic acid for treatment of multicentric Castleman's disease. Lancet 1999; 354:1262-3.
96. Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet 2004;363:1802-11.
97. Jung CP, Emmerich B, Goebel FD, Bogner JR. Successful treatment of a patient with HIV-associated multicentric Castleman disease (MCD) with thalidomide. Am J Hematol 2004; 75:176-7.
98. Lee FC, Merchant SH. Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide. Am J Hematol 2003;73:48-53.
99. Beck JT, Hsu SM, Wijdenes J, et al. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 1994;330:602-5.
100. Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000;95:56-61.
101. Nishimoto N. Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan. Clin Rev Allergy Immunol 2005;28:221-30.
102. van Rhee F, Fayad L, Voorhees P, et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol 2010;28:3701-8.
103. Ahmed B, Tschen JA, Cohen PR, et al. Cutaneous castleman's disease responds to anti interleukin-6 treatment. Mol Cancer Ther 2007;6:2386-90.
104. Kedes DH, Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest 1997;99:2082-6.
105. Medveczky MM, Horvath E, Lund T, Medveczky PG. In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus. AIDS 1997;11:1327-32.
106. Neyts J, De Clercq E. Antiviral drug susceptibility of human herpesvirus 8. Antimicrob Agents Chemother 1997;41:2754-6.
107. Bottieau E, Colebunders R, Schroyens W, et al. Multicentric Castleman's disease in 2 patients with HIV infection, unresponsive to antiviral therapy. Acta Clin Belg 2000;55:97-101.
108. Senanayake S, Kelly J, Lloyd A, Waliuzzaman Z, Goldstein D, Rawlinson W. Multicentric Castleman's disease treated with antivirals and immunosuppressants. J Med Virol 2003;71:399-403.
109. Revuelta MP, Nord JA. Successful treatment of multicentric Castleman's disease in a patient with human immunodeficiency virus infection. Clin Infect Dis 1998;26:527.
110. Nord JA, Karter D. Low dose interferon-alpha therapy for HIV-associated multicentric Castleman's disease. Int J STD AIDS 2003;14:61-2.
111. Corbellino M, Bestetti G, Scalamogna C, et al. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 2001;98:3473-5.
112. Berezne A, Agbalika F, Oksenhendler E. Failure of cidofovir in HIV-associated multicentric Castleman disease. Blood 2004; 103:4368-9.
113. Casper C, Nichols WG, Huang ML, Corey L, Wald A. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood 2004;103:1632-4.
114. Zoeteweij JP, Eyes ST, Orenstein JM, et al. Identification and rapid quantification of early- and late-lytic human herpesvirus 8 infection in single cells by flow cytometric analysis: characterization of antiherpesvirus agents. J Virol 1999;73:5894-902.
115. Oksenhendler E. HIV-associated multicentric Castleman disease. Curr Opin HIV AIDS 2009;4:16-21.
116. Bower M, Powles T, Williams S, et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med 2007;147:836-9.
117. Parravicini C, Chandran B, Corbellino M, et al. Differential viral protein expression in Kaposi's sarcoma-associated herpesvirusinfected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Am J Pathol 2000;156: 743-9.
118. Marcelin AG, Aaron L, Mateus C, et al. Rituximab therapy for HIV-associated Castleman disease. Blood 2003;102:2786-8.
119. Stebbing J, Gazzard B, Newsom-Davis T, et al. Nadir B cell counts are significantly correlated with the risk of Kaposi's sarcoma. Int J Cancer 2004;108:473-4.
120. Gerard L, Berezne A, Galicier L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol 2007;25:3350-6.
121. Lanzafame M, Carretta G, Trevenzoli M, Lazzarini L, Vento Ercole Concia S. Successful treatment of Castleman's disease with HAART in two HIV-infected patients. J Infect 2000;40: 90-1.
122. Loi S, Goldstein D, Clezy K, Milliken ST, Hoy J, Chipman M. Castleman's disease and HIV infection in Australia. HIV Med 2004;5:157-62.
123. Liberopoulos E, Tolis C, Bai M, Efremidis S, Pavlidis N, Elisaf M. Successful treatment of human immunodeficiency virus-related Castleman's disease: a case report and literature review. Oncology 2003;65:182-6.
124. Newsom-Davis T, Bower M, Wildfire A, et al. Resolution of AIDS-related Castleman's disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNF-alpha levels. Leuk Lymphoma 2004;45:1939-41.